FIGURE 3

Effect on Hemoglobin A1c ( HbA1c ) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist ...

FIGURE 4: Change in HbA1c values over the course of the trial and two, four, and six months after drug discontinuation - " Effect on Hemoglobin A1c ( HbA1c ) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series ...
PDF Effect on Hemoglobin A1c (HbA1c) and Body Weight After ...

Fifty-two weeks after randomization, study drug administration was discontinued. To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug.
To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug. Results After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group.

Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation ...
After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group. At two, four, and six months after the end of study drug administration, re-elevation of HbA1c was observed in all groups.
Given a similar, if not superior, effectiveness for HbA1c reduction with additional weight reduction and no intrinsic risk of hypoglycemic episodes, GLP-1RAs are recommended as the preferred first ...

Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation ...
Clinical trials have shown that tirzepatide significantly reduces HbA1c levels and induces substantial weight reduction, and this work reports two cases of diabetes remission after temporary tirzepatide therapy.
The duration of the off-drug treatment period was 4 weeks, which is not enough to affect HbA1c and body weight fully or determine the long-term effects of discontinuing tirzepatide treatment.

Key Details About Figure 3 From Effect On Hemoglobin A1C Hba1C And Body Weight After
TZP was more efficacious than placebo or SEMA in reducing HbA1c and BW across a spectrum of pancreatic beta-cell function, notably achieving greater glycemic improvement in people with markers of diminished pancreatic beta cell function at baseline.






High-dose tirzepatide is associated with superior HbA1c reduction and weight loss compared with semaglutide in type 2 diabetes and obesity.